title: Viability of red cells prepared with S-303 pathogen inactivation treatment.
abstract: BACKGROUND
  A nucleic acid-targeted pathogen inactivation process with S-303 was developed to treat red blood cells (RBCs).
  
  
  METHODS
  Three studies in healthy subjects investigated posttransfusion recovery, life span, and immunogenic potential of autologous RBCs treated with S-303 and stored for 35 days. A two-arm trial in 42 subjects (1A) examined recovery of 35-day-old S-303 RBCs after a single transfusion. A one-arm study (1B) measured recovery and immune response in 28 subjects after multiple transfusions of S-303 RBCs. A randomized, crossover study (1C) in 29 subjects compared recovery and life span of 35-day-old S-303 RBCs and conventional RBCs.
  
  
  RESULTS
  In Studies 1A and 1B, mean recovery of S-303 RBCs ranged from 78.7 to 84.4 percent. In Phase 1C, the mean 24-hour posttransfusion recoveries of S-303 and untreated RBCs were 81.7 +/- 6.3 and 84.5 +/- 6.2 percent (p = 0.05). The median life spans (t(1/2)) of S-303 and control RBCs were identical (37.4 days, p = 0.98). No antibodies to S-303 RBCs were detected.
  
  
  CONCLUSIONS
  The mean 24-hour recovery of 35-day-old S-303 RBCs was less than untreated RBCs, but greater than 75 percent. RBCs treated with S-303 and stored for 35 days exhibited median life span not different from that of conventional RBCs.
authors.affiliation: American Red Cross Blood Services, Dedham, Massachusetts, USA.
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Rios
authors.forename: Julie
authors.initials: J
authors.lastname: Hambleton
authors.forename: Maurene
authors.initials: M
authors.lastname: Viele
authors.forename: Neeta
authors.initials: N
authors.lastname: Rugg
authors.forename: Gail
authors.initials: G
authors.lastname: Sindermann
authors.forename: Tibor
authors.initials: T
authors.lastname: Greenwalt
authors.forename: David
authors.initials: D
authors.lastname: Wages
authors.forename: David
authors.initials: D
authors.lastname: Cook
authors.forename: Laurence
authors.initials: L
authors.lastname: Corash
mesh_terms: D000166:Acridines / Q000494:pharmacology*; D001793:Blood Preservation / Q000295:instrumentation / Q000379:methods; D001804:Blood Transfusion, Autologous; D002470:Cell Survival / Q000187:drug effects; D004203:Disinfection / Q000295:instrumentation / Q000379:methods; D017707:Erythrocyte Transfusion; D004912:Erythrocytes; D006801:Humans; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D013997:Time Factors
chemical_list: C506266:(N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate; D000166:Acridines; D009588:Nitrogen Mustard Compounds